CDKN2A and meningioma: Additionally, our findings suggest that elevated CDKN2A mRNA expression in meningiomas may serve as a biomarker of clinical aggressiveness in the majority of meningiomas that do not have any CDKN2A deletions (homodel or heterodel), presenting interesting diagnostic and therapeutic implications.